Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced on March 10, 2022, that Dr. Fahar Merchant, President and CEO, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15 to March 17, 2022. The presentation is scheduled for 8:00 a.m. EST on March 15. A webcast link is provided for attendees. Medicenna focuses on immunotherapy, exploring innovative treatments such as its long-acting IL-2 Superkine, MDNA11, and MDNA55, aimed at addressing challenging cancers, including glioblastoma.

TORONTO and HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 32^nd Annual Oppenheimer Healthcare Conference, which is scheduled to take place virtually from March 15 – March 17, 2022.

Details are as follows:

32nd Annual Oppenheimer Healthcare Conference
Date:	Tuesday, March 15th
Time:	8:00 a.m. EST
Location:	Webcast Link

Webcast and replay information for these events will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com   

Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com 

FAQ

When is Medicenna's presentation at the Oppenheimer Healthcare Conference?

Medicenna's presentation is scheduled for 8:00 a.m. EST on March 15, 2022.

Where can I watch Medicenna's conference presentation?

You can watch Medicenna's presentation via the webcast link.

What is the focus of Medicenna Therapeutics?

Medicenna focuses on developing novel immunotherapies, including Superkines like MDNA11 and MDNA55, targeted at treating various cancers.

What notable trials has MDNA55 undergone?

MDNA55 has been studied in five clinical trials, including a Phase 2b trial for recurrent glioblastoma.

What is the ticker symbol for Medicenna Therapeutics?

The ticker symbol for Medicenna Therapeutics is MDNA, listed on both NASDAQ and TSX.